Tag: Novartis

Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...

NIH and partners to assess whether Omalizumab can reduce allergic reactions.
Perplexed Pharmacist

FDA Confirms Adrenaclick® Generic and EpiPen® Still in Short Supply with...

Shortages of auto-injectors continue. Consider these alternatives.
Americares

Protecting Against Severe Allergic Reactions This Summer

Life-saving medication on the way to U.S. clinics serving low-income and uninsured patients.
Symjepi

Symjepi, the Auto-Injector Alternative, to Launch Q1 2019

Prefilled syringe will join auto-injectors for emergency delivery of epinephrine.
Xolair (omalizumab)

FDA Grants Xolair Breakthrough Therapy Designation for Food Allergies

Breakthrough Therapy Designation was granted on the basis of data from seven clinical studies assessing the efficacy and safety of Xolair against a range of food allergens including peanut, milk, egg and others.
Symjepi

Symjepi Back on Track After Adamis Finds Commercialization Partner

Partnership paves way for introduction of device already approved by the FDA.

Connect with Us

39,158FansLike
781FollowersFollow
2,716FollowersFollow
5,529FollowersFollow
40SubscribersSubscribe